Gavin Clark has 38 years of experience in the biopharma industry. After a brief spell as Chemist at J&J (Ethicon) Gavin he moved into commercial positions at Janssen, Bayer and Novartis. Between 1994-99 he was responsible for Global Licensing Infectious Diseases at GlaxoWellcome and thereafter at Belgium/Ireland based Tibotec Pharmaceuticals. At Tibotec he was responsible for business development until the acquisition by Johnson & Johnson in 2002.
Since then he has been active in his role as Managing Director of Marlin Bioconsulting Ltd and has consulted in a variety of commercial roles and has worked on a number of fundraising, Mergers & Acquisitions and Licensing deals for the mostly SME client base in the US, Asia Pacific and the EU. In 2009 he cofounded, and was Chief Business Officer until 2013 at Glasgow based MGB Biopharma Limited, a company which is developing one of the few truly novel classes of antibiotics based on DNA minor groove binder discovery originated by Strathclyde University.
Gavin is Non-Executive Director at Lamellar Biomedical Ltd, representing the investment interests there of Scottish Enterprise. He is a Certified Licensing Professional (CLP), as accredited by the Licensing Executives Society North America. He also serves as a member of the Advisory Board of the Scottish Lifesciences Association and an Enterprise Partner of Strathclyde University in Glasgow.